Comparative Pharmacology
Head-to-head clinical analysis: OGESTREL 0 5 50 28 versus TRI SPRINTEC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OGESTREL 0 5 50 28 versus TRI SPRINTEC.
OGESTREL 0.5/50-28 vs TRI-SPRINTEC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive; suppresses gonadotropins (FSH, LH) via negative feedback on hypothalamic-pituitary axis, inhibiting ovulation; increases cervical mucus viscosity and alters endometrial development.
Combination of ethinyl estradiol and norgestimate suppresses gonadotropin release, inhibiting ovulation, and increases viscosity of cervical mucus to inhibit sperm penetration.
One tablet (norgestrel 0.5 mg/ethinyl estradiol 50 mcg) orally once daily for 28-day cycle.
One tablet (0.035 mg ethinyl estradiol / 0.250 mg norgestimate) orally once daily for 21 days, followed by 7 days of placebo tablets. Repeat cycle.
None Documented
None Documented
Norgestrel: ~45 hours (range 24-56 h) enabling once-daily dosing; Ethinyl estradiol: ~17 hours (range 10-27 h).
Norelgestromin: 28 hours; Ethinyl estradiol: 17 hours. Steady-state achieved within 7 days.
Renal: 50-60% as metabolites (glucuronide and sulfate conjugates of norgestrel and ethinyl estradiol); Fecal: 30-40% via biliary elimination; Unchanged drug: <1%.
Renal: 50% (metabolites); Fecal: 35% (eliminated in bile); unchanged drug <1%.
Category C
Category C
Oral Contraceptive
Oral Contraceptive